N
NanoMosaic Inc
Nanoneedle platform for proteomic and multi-omic analysis
About NanoMosaic Inc
NanoMosaic Inc., founded in 2018 by John Boyce and Qimin Quan, is a biotechnology company developing tools for biomarker detection and analysis. The company is headquartered in Woburn, Massachusetts. John Boyce, also the co-founder of the venture capital firm Tiger Gene L.L.C., provided initial funding and leadership. Qimin Quan, who serves as the Chief Scientific Officer, has a background in Applied Physics from Harvard University, where his interdisciplinary research laid the groundwork for the company's core technology. In December 2023, Philippe Mourere was appointed CEO, with John Boyce becoming Executive Chairman and Joe Wilkinson taking the role of President and COO.
The company's core business revolves around its proprietary nanoneedle technology, which is designed for advanced protein and multi-omic interrogation. NanoMosaic's flagship system, the Tessie™, is a benchtop instrument that, along with Nanoplate consumables, enables high-throughput, label-free analysis of proteins and nucleic acids directly from crude samples like plasma. This technology serves researchers in life sciences, diagnostics, and pharmaceutical development by providing a platform for biomarker discovery, validation, and diagnostic test development. The business model involves the sale of the Tessie™ instrument and recurring revenue from the sale of consumable Nanoplates. The system is designed to be accessible, with a workflow comparable to a standard ELISA and compatibility with existing lab automation.
The Tessie™ platform's key features include its ability to analyze proteins and nucleic acids on the same chip, a dynamic range spanning over seven orders of magnitude, and high sensitivity. This allows for the detection of low-abundance biomarkers critical for applications in neurology, immunology, and gene therapy. For instance, the platform is used for quantifying AAV gene therapy capsids and their payloads, as well as detecting neurology biomarkers for conditions like Alzheimer's disease. The company closed a $40.75 million Series A funding round in December 2021, led by RA Capital Management, to expand its commercial infrastructure and application development.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2021 | $41M | $163M | RA Capital Management · Insight Partners · Pura Vida Investments · Time BioVentures | ↗ |
Growth signals
Latest recorded traffic for NanoMosaic Inc is 1.1K monthly website visits, up 37.5% over the last three months. NanoMosaic Inc's team grew 0% over the past year.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
NanoMosaic Inc in the Waltham ecosystem
The NanoMosaic Inc office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
RA Capital Management
Insight Partners- PIPura Vida Investments
Time BioVentures
TigerGene
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NanoMosaic Inc on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NanoMosaic Inc’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.